News single

Bill Koschak

Chief Financial Officer

Bill brings over brings over 10 years of corporate, finance and accounting leadership to Calyxt as an operating or corporate CFO. Prior to joining Calyxt, Bill was Vice President, Finance for the Brain Therapies business unit of Medtronic (NYSE: MDT). He has held executive positions at Young America Holdings, General Mills (NYSE:GIS), and KPMG LLP. Bill was recognized as a CFO of the Year by the Twin Cities Business Journal in 2016 and currently serves on the board of 1st Financial Bank USA.

Yves Ribeill, Ph.D.

Executive Chairman

Dr. Yves Joseph Ribeill, Ph.D. Founded Scynexis, Inc (NASDAQ: SCYX) and served as its President from November 1999 to July 2015 and served as its Chief Executive Officer from November 1999 to April 1, 2015. Prior to organizing Scynexis, Inc. in 2000, Dr. Ribeill served various positions during the 25 years of his international career with Rhone-Poulenc, Aventis including Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He served as Group Leader in the Cardiovascular Group in England. Upon his return to France, Dr. Ribeill served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs. He has been a Director of various Biotech companies in Europe and the US. He served as a Director of Scynexis, Inc. from November 1999 to March 16, 2016. He is the author of more than 26 publications and 15 patents. He was a member of the Scientific Advisory Committee of the World Health Organization and of the Medicine Malaria Venture in Geneva. Dr. Ribeill has a Ph.D. in Chemistry from the University of Montpellier (France).

André Choulika, Ph.D.

Chairman and Director

André Choulika, Ph.D., has served as Chairman of our Board of Directors since August 2010. Dr. Choulika is one of the founders of Cellectis and has served as Chief Executive Officer of Cellectis since the company’s inception in 1999. He has served as the Chairman of the Board of Directors of Cellectis since 2011. Since December 2014, Dr. Choulika has served as Chief Executive Officer of Cellectis, Inc. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from HEC (Challenge +).

Dan Voytas, Ph.D.

Calyxt Scientific Advisory Board Chair and Professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota

Dan graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is a co-founder of Calyxt and one of the inventors of the TALEN® technology. In addition to his role at Calyxt, Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN), which he joined in 2008, and is Director of the UMN’s Center for Precision Plant Genomics. In 1992, Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dan is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Sciences.